Compare JPMorgan Diversified Return International Eqty ETF (JPIN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Diversified Return International Eqty ETF vs State Street SPDR S&P Biotech ETF — how do they compare? JPMorgan Diversified Return International Eqty ETF trades at $74.13, while State Street SPDR S&P Biotech ETF trades at $151.81. Which is the better fit depends on your goals.
| JPIN | XBI | |
|---|---|---|
52-Week High | $76.96 | $164.28 |
52-Week Low | $63.14 | $85.16 |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPIN, the JPMorgan Diversified Return International Equity ETF, trades at $73.11, down 0.5% on the day. Technical indicators show a bullish trend with strong moving average support, while oscillators are neutral. The ETF provides broad exposure to international large-cap value stocks, utilizing a smart-beta strategy for diversification. A dividend of $0.91 is scheduled for payment on June 25, 2026.
The ETF's outlook is supported by its diversified international equity approach, though it faces risks from global market volatility and currency fluctuations. Key resistance is at $74, with support at $73. The bullish technical setup suggests potential for near-term gains, but investors should weigh the inherent risks of international investing.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
